NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
EDEN PRAIRIE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first implant of its OneRF™ Ablation electrode by doctors at a top ranked hospital in the US, as ranked by the US News & World Best Hospital Report in its 2023-2024 publication. The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures.
- The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures.
- “We are excited to announce that yesterday, doctors implanted Evo® sEEG-RF electrodes in a patient suffering from epilepsy.
- Once the monitoring identifies the areas of the brain that are causing seizures, the surgical team now has the option to use the same electrodes to perform an ablation utilizing NeuroOne’s RF generator.
- NeuroOne now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode.